Specifically, inhibitors targeting vascular endothelial growth factor (VEGF) have emerged as powerful tools in managing angiogenesis-dependent disorders like cancer and diabetic retinopathy, due to their capacity to inhibit angiogenesis. The gene discussed is VEGFA; the disease is diabetic retinopathy.